A Randomized, Double-blind, Placebo-Controlled, Three-part Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-951 in Healthy Subjects
Latest Information Update: 15 Sep 2023
At a glance
- Drugs TAK 951 (Primary)
- Indications Nausea and vomiting
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
- 07 Oct 2022 New trial record